Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Multiple Myeloma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced May 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
707
Shown on this page
12
Local recruiting
141
Local phase groups
6
The trial list below is retrieved from the live ClinicalTrials.gov search API for Multiple Myeloma. Results on this page are currently sorted by Recently updated.

How Multiple Myeloma studies are organized in the registry

Myeloma listings distinguish newly diagnosed from relapsed/refractory disease in their titles, and precursor conditions — smoldering myeloma and MGUS — are usually registered as separate condition terms. Cell-based and antibody platforms (CAR-T, bispecific antibodies) appear by name in many current titles.

  • 20% of the 707 locally indexed Multiple Myeloma records are currently marked recruiting.
  • The most common phase group in the local index is Phase 2 (335 records).
  • The most frequent sponsor is Janssen Research & Development, LLC (31 records).
  • The most listed study location is New York, New York (218 records).
Terms that often appear in related listings
relapsed refractory myeloma smoldering myeloma CAR-T bispecific

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Multiple Myeloma. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 707 matching trials for Multiple Myeloma.
Indexed local directory records.

Phase distribution

Phase 2 335
Phase 1 260
Phase 3 64
Not applicable 56
Early Phase 1 8
Phase 4 7

Top locations

New York, New York 218 Boston, Massachusetts 171 Atlanta, Georgia 118 Houston, Texas 111 Nashville, Tennessee 90 St Louis, Missouri 88

Top sponsors

Janssen Research & Development, LLC 31 Memorial Sloan Kettering Cancer Center 30 Celgene 24 National Cancer Institute (NCI) 23 Massachusetts General Hospital 20 University of Arkansas 19

Top therapies

Dexamethasone 148 Lenalidomide 84 Bortezomib 65 Daratumumab 54 Pomalidomide 51 Carfilzomib 45

Indexed official records

Open in full search
Recruiting Phase 1 Interventional

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

NCT07409246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-438
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 11:51 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Dexamethasone, Etentamig, Lenalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2042
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 6:47 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig (ABBV-383)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 11:51 PM EDT
Recruiting Phase 2 Interventional

Halt Aging in Survivors of Blood Cancers

NCT07292272
View directory record Official record
Conditions
Hematological Malignancy, Leukemia, Lymphoid Leukemia, Monocytic Leukemia, Multiple Myeloma, Myeloid Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition
Interventions
Behavioral Coaching Intervention, Virtual Exercise Platform
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 1:52 AM EDT
Recruiting Not applicable Interventional

Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)

NCT07102212
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Melanoma, Multiple Myeloma, Prostate Cancer
Interventions
mHealth Intervention
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480
View directory record Official record
Conditions
Multiple Myeloma, Secondary Immunodeficiency
Interventions
IGI, 10%
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Bortezomib, Carfilzomib, Dexamethasone, Pomalidomide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Torrance, California • Fort Myers, Florida • Macon, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 2 Interventional

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions
Abemaciclib, Atezolizumab and Talazoparib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD), Futibatinib, Nivolumab and Ipilimumab, Olaparib, Palbociclib, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
12 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
174
States / cities
Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

NCT06215118
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Iberdomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
34
States / cities
Coral Gables, Florida • Deerfield Beach, Florida • Doral, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Etentamig, Pomalidomide, Selinexor
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Elranatamab, Pomalidomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
97
States / cities
Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 1:22 AM EDT

About this Multiple Myeloma clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Multiple Myeloma.